Chronic Lymphocytic Leukemia

Anthony R. Mato, MD, hematologic oncologist, director, CLL Program, Memorial Sloan Kettering Cancer Center, discusses a phase II trial of umbralisib in chronic lymphocytic leukemia.

Matthew S. Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, discusses duvelisib in relapsed/refractory chronic lymphocytic leukemia.

Antibody-drug conjugates represent a targeted class of agents with an improved therapeutic index over traditional chemotherapy in the treatment of non-Hodgkin lymphoma.

Anthony R. Mato, MD, hematologic oncologist, director, CLL Program, Memorial Sloan Kettering Cancer Center, discusses the safety and efficacy of umbralisib in patients with chronic lymphocytic leukemia.

The combination of duvelisib and fludarabine-cyclophosphamide-rituximab demonstrated efficacy as a frontline treatment for younger patients with chronic lymphocytic leukemia.

Matthew Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, discusses duvelisib plus fludarabine-cyclophosphamide-rituximab (FCR) as a frontline therapy for the treatment of younger patients with chronic lymphocytic leukemia.

The combination of obinutuzumab and chlorambucil reduced the risk of death by 24% versus rituximab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia with comorbidities.

The FDA has granted a regular approval to venetoclax for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, with or without 17p deletion, following at least 1 prior therapy. The BCL-2 inhibitor is now also approved for use in combination with rituximab in the same patient population.

The frontline combination of ibrutinib and venetoclax demonstrated a 100% objective response rate for patients with chronic lymphocytic leukemia, with 77% of patients testing negative for minimal residual disease in the peripheral blood after 6 cycles.

Frontline treatment with the combination of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) improved progression-free survival compared with chlorambucil plus obinutuzumab in patients with CLL or SLL.

Ryan W. Jacobs, MD, discusses the use of small molecule inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the frontline treatment of patients with chronic lymphocytic leukemia.

Experts offer their perspectives on developments in the field of chronic lymphocytic leukemia, such as novel combinations and emerging agents.

Alan Skarbnik, MD, staff physician, Department of Bone Marrow Transplantation and Department of Lymphoma, John Theurer Cancer Center, discusses the changing treatment landscape of chronic lymphocytic leukemia.

Results from a recent study may show why some patients with chronic lymphocytic leukemia are resistant to tisagenlecleucel, while potentially offering a pathway to enhance patient response.

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the prognosis of patients with chronic lymphocytic leukemia.

Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the use of ibrutinib (Imbruvica) in high-risk patients with chronic lymphocytic leukemia (CLL).

Neil E. Kay, MD, professor of medicine, Mayo Clinic, discusses combination strategies for patients with chronic lymphocytic leukemia (CLL).

The FDA has granted a priority review to a new drug application for duvelisib for a full approval for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and an accelerated approval for the treatment of patients with relapsed/refractory follicular lymphoma.

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the challenges facing the field of chronic lymphocytic leukemia (CLL).

Alan Skarbnik, MD, shares his insight on the latest updates in chronic lymphocytic leukemia presented at the 2017 ASH Annual Meeting.